Latest Moberg Pharma News & Updates

See the latest news and media coverage for Moberg Pharma. We track all announcements, press releases, and industry mentions in real time, all in one place.

Moberg Pharma

Commercial-stage dermatology pharmaceutical company

mobergpharma.se

Headquarters: Bromma, Sweden
Founded year: 2006
Company type: Public company
Number of employees: 18–50
Industry: Pharmaceuticals

Last updated August 13

Latest news about Moberg Pharma

In short: Moberg Pharma expanded Terclara markets and narrowed its Q1 loss

Company announcements

August 13 Moberg Pharma

Moberg Pharma reports increased revenue and expands partnerships

The license agreement with Karo Healthcare was expanded to APAC and China, and the first European countries approved the brand change for MOB-015.

May 12 Moberg Pharma

Moberg Pharma expands license agreement with Karo Healthcare to APAC

The agreement covers Australia, New Zealand, South Korea and Taiwan, where Karo is market leading. Q1 revenue amounted to SEK 4.9 million.

April 24 Moberg Pharma

Moberg Pharma expands collaboration with Karo Healthcare

The agreement licenses MOB-015/Terclara to Australia, New Zealand, South Korea, and Taiwan under Lamisil brand. It builds on European partnership.

April 17 Moberg Pharma

Moberg Pharma releases annual report 2025

The report is published in accordance with EU Market Abuse Regulation on April 17, 2026. Contact details for CEO Anna Ljung and CFO Mark Beveridge are provided.

Media coverage

August 10 Finanznachrichten

Moberg Pharma AB: Moberg Pharma's Interim report January - June 2026

APPROVED TRADEMARK CHANGE IN THE FIRST EUROPEAN COUNTRIES AND LICENSE AGREEMENTS FOR APAC AND CHINA SIX-MONTH PERIOD (JAN-JUN 2026) Net revenue SEK 10.7 million (7.5...

May 12 Dagens industri

Reduced losses for Moberg Pharma - revenue increased

The pharmaceutical company Moberg Pharma reports a net loss of SEK 1.3 million for the first quarter of 2026 (loss of SEK 2.8 million). The result...

February 17 Finanznachrichten

Moberg Pharma AB: Moberg Pharma Year-end report 2025

Net revenue SEK 13.5 million (9.8) EBITDA SEK -25.7 million (-23.5) Operating profit (EBIT) SEK -27.3 million (-324.8) Profit for the period SEK -27.2 million...

November 4, 2025 Realtid

Karo Healthcare enters an exclusive license agreement with Moberg Pharma for MOB-015 in Europe

Redan godkända solparker kan producera mer än nio terawattimmar (TWh) el, nästan lika mycket som användningen av hushållsel i alla Sveriges två miljoner småhus. Det...

Never miss news about Moberg Pharma

Track Moberg Pharma and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Moberg Pharma competitors & trending companies

Browse news for competitors to Moberg Pharma and other trending companies.